Condition: Breast Cancer
Intervention: Drug: Temsirolimus plus Neratinib
Sponsors: Memorial Sloan-Kettering Cancer Center; National Comprehensive Cancer Network; Wyeth Pharmaceuticals, Inc., a Pfizer Company
Recruiting - verified August 2010
Feeds
4318 items (4318 unread) in 87 feeds
Acinar Cell Carcinoma
(24 unread)
Acinic Cell Carcinoma
(33 unread)
Adenoid Cystic Carcinoma
(83 unread)
Adrenal Gland Cancer
(305 unread)
Ampulla Of Vater
(23 unread)
Anal Cancer
(212 unread)
Angiosarcoma
(79 unread)
Appendix Cancer
(66 unread)
Bile Duct Cancer
(332 unread)
Brain and CNS
(1194 unread)
Carcinoid
(124 unread)
Endocrine/Neuroendocrine
(500 unread)
Gall Bladder Cancer
(89 unread)
General
(4 unread)
Hemangioendothelioma
(38 unread)
HemeOnc
(78 unread)
Hepatoblastoma
(46 unread)
Pancreas
(76 unread)
Phyllodes
(21 unread)
PMP and Mucinous Tumors
(35 unread)
Rhabdomyosarcoma
(175 unread)
Sarcoma
(313 unread)
Twitter Pals
(468 unread)
Trial - Appendix Cancer (15 unread)
-
Temsirolimus Plus Neratinib for Patients With Metastatic HER2-Amplified or Triple Negative Breast Cancer
Posted: April 22nd, 2010, 9:00am CDT
-
Study to Evaluate the Efficacy and Safety of Treatment With Bendamustine in Combination With Ofatumumab in Previously Untreated Patients With Indolent B-Cell Non-Hodgkin's Lymphoma (NHL)
Posted: April 14th, 2010, 9:00am CDT
Condition: Non-Hodgkin's Lymphoma (NHL)
Intervention: Drug: Bendamustine and Ofatumumab
Sponsor: Cephalon
Recruiting - verified August 2010 -
Breast-Conserving Surgery Followed by Radiation Therapy in Treating Patients With MRI-Detected Stage I or Stage II Breast Cancer
Posted: April 7th, 2010, 9:00am CDT
Conditions: Ductal Breast Carcinoma in Situ; Estrogen Receptor-negative Breast Cancer; Estrogen Receptor-positive Breast Cancer; HER2-negative Breast Cancer; HER2-positive Breast Cancer; Invasive Ductal Breast Carcinoma; Invasive Lobular Breast Carcinoma; Male Breast Cancer; Medullary Ductal Breast Carcinoma With Lymphocytic Infiltrate; Mucinous Ductal Breast Carcinoma; Papillary Ductal Breast Carcinoma; Progesterone Receptor-negative Breast Cancer; Progesterone Receptor-positive Breast Cancer; Stage I Breast Cancer; Stage II Breast Cancer; Tubular Ductal Breast Carcinoma
Interventions: Radiation: external beam radiation therapy; Other: questionnaire administration; Procedure: therapeutic conventional surgery
Sponsor: Case Comprehensive Cancer Center
Recruiting - verified June 2010 -
Pharmacokinetics (PK) Study of AC480 for Recurrent Glioma
Posted: August 6th, 2009, 9:00am CDT
Condition: Glioma
Intervention: Drug: AC480
Sponsors: Duke University; Ambit Biosciences
Recruiting - verified May 2010 -
Palonosetron Hydrochloride in Preventing Nausea and Vomiting Caused by Radiation Therapy in Patients With Primary Abdominal Cancer
Posted: May 15th, 2009, 9:00am CDT
Conditions: Anal Cancer; Carcinoma of the Appendix; Colorectal Cancer; Extrahepatic Bile Duct Cancer; Gallbladder Cancer; Gastric Cancer; Gastrointestinal Carcinoid Tumor; Liver Cancer; Nausea and Vomiting; Pancreatic Cancer; Peritoneal Cavity Cancer; Small Intestine Cancer
Interventions: Drug: palonosetron hydrochloride; Other: placebo
Sponsors: North Central Cancer Treatment Group; National Cancer Institute (NCI)
Recruiting - verified August 2010 -
Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain
Posted: October 1st, 2007, 9:00am CDT
Condition: Cancer
Interventions: Drug: fentanyl sublingual spray; Other: questionnaire administration
Sponsor: Insys Therapeutics Inc
Recruiting - verified October 2008 -
Randomized Anastrozole Exercise Trial
Posted: August 22nd, 2007, 9:00am CDT
Condition: Musculoskeletal Symptoms
Interventions: Other: Exercise; Other: Supportive Care
Sponsor: British Columbia Cancer Agency
Active, not recruiting - verified August 2010 -
A Clinical Trial Assessing Efficacy and Safety of Sunitinib and Exemestane in Patients With ER [Estrogen Receptor] + and/or PgR [Progesterone Receptor] + Breast Cancer
Posted: January 2nd, 2007, 9:00am CST
Condition: Breast Neoplasms
Interventions: Drug: exemestane; Drug: sunitinib malate
Sponsor: Pfizer
Terminated - verified August 2010 -
Erlotinib and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, or Colorectal Cancer
Posted: November 8th, 2006, 9:00am CST
Condition: Cancer
Interventions: Biological: cetuximab; Drug: erlotinib hydrochloride; Genetic: proteomic profiling; Other: laboratory biomarker analysis
Sponsors: Vanderbilt-Ingram Cancer Center; National Cancer Institute (NCI)
Recruiting - verified January 2009 -
Study of Velcade® and Bone Formation in Patients With Relapsed/Refractory Multiple Myeloma
Posted: August 8th, 2005, 9:00am CDT
Condition: Multiple Myeloma
Intervention: Drug: VELCADE™
Sponsor: University of Arkansas
Completed - verified July 2010 -
Hepatic Arterial Infusion of Melphalan With Hepatic Perfusion in Treating Patients With Unresectable Liver Cancer
Posted: November 9th, 2004, 9:00am CST
Condition: Cancer
Interventions: Drug: isolated perfusion; Drug: melphalan
Sponsor: National Cancer Institute (NCI)
Active, not recruiting - verified July 2009 -
Study of KIR-Ligand Mismatched Haplo-Identical Natural Killer Cells Transfused Before Autologous Stem Cell Transplant
Posted: August 5th, 2004, 9:00am CDT
Condition: Multiple Myeloma
Interventions: Drug: Dexamethasone; Drug: Cyclophosphamide; Drug: Melphalan; Drug: Fludarabine; Drug: Bortezomide; Procedure: Leukapheresis; Drug: Interleukin; Procedure: Infusion #1; Procedure: Leukapheresis #2; Procedure: Infusion #2; Procedure: Auto Graft
Sponsor: University of Arkansas
Completed - verified June 2010 -
Thalidomide and Docetaxel in Treating Patients With Advanced Cancer
Posted: November 12th, 2002, 9:00am CST
Condition: Cancer
Interventions: Drug: docetaxel; Drug: thalidomide
Sponsors: Case Comprehensive Cancer Center; National Cancer Institute (NCI)
Completed - verified June 2010 -
MS-275 in Treating Patients With Advanced Solid Tumors or Lymphoma
Posted: July 11th, 2001, 9:00am CDT
Condition: Cancer
Intervention: Drug: entinostat
Sponsor: National Cancer Institute (NCI)
Completed - verified February 2007 -
Interleukin-12 in Treating Patients With Cancer in the Abdomen
Posted: November 1st, 1999, 9:00am CST
Conditions: Anal Cancer; Colorectal Cancer; Gallbladder Cancer; Gastric Cancer; Pancreatic Cancer
Intervention: Biological: Recombinant Interleukin-12
Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI)
Completed - verified August 2010